AAPGAscentage Pharma Group Inc.Signing up patients
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
T-Prolymphocytic Leukemia · Non-Hodgkins Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 78 (planned)
- Started
- Jul 12, 2021
- Main results expected
- May 31, 2026
- Fully finished
- May 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Maximum tolerated dose of APG-115
Measured over: 21 days
Maximum tolerated dose of APG-115+APG-2575
Measured over: 21 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04496349 · record last updated 2025-11-04 · checked 2026-11-09 15:42 UTC